Biologics

Goldman Sachs listed DiscGenics CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021, according to an Oct. 18 news release.

Bone Therapeutics appointed a five-person scientific advisory board for guidance on developing induced pluripotent stem cell-derived mesenchymal stromal cell, the company said Oct. 12.

Pacira BioSciences signed an agreement to acquire Flexion Therapeutics, according to an Oct. 11 news release.

Virginia Beach, Va.-based LifeNet Health launched the ViviGen minimally invasive surgery delivery system.

Regenerative medicine remains a hot topic among spine and orthopedic surgeons. From stem cell treatments to bone grafts, biologic technology is growing, and many surgeons are optimistic.

The regenerative medicine market is expected to hit $172.15 billion by 2030, according to market research from Next Move Strategy Consulting.

Here are seven updates in orthopedic biologics in the last 90 days:

A new clinic in Honolulu focuses on non-surgical treatments for orthopedic injuries.

One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal.

Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release.